Business
Media
Conferences
Publications
CME/CE
Resources
Subscribe

Opinion|Videos|September 3, 2024

The Importance of Serum Testosterone Levels With the Use of Androgen Receptor-Targeting Therapies

Author(s)Gautam Jayram, MD, Christopher Pieczonka, MD

Panelists discuss how the STAAR study (Stein, 2018) indicates that the micronized abiraterone formulation results in lower average serum testosterone levels in 25% of patients compared to 17% with the originator formulation, potentially influencing treatment selection.

Episodes in this series

2 KOLs are featured in this series.

EP. 1 Expert Perspective on the Expanding Treatment Landscape in mCRPC

2 KOLs are featured in this series.

EP. 2 The Role of Androgen Receptor-Targeted Therapy in the Treatment of mCRPC

2 KOLs are featured in this series.

EP. 3 Management of Comment Adverse Effects Associated with mCRPC Therapies

2 KOLs are featured in this series.

EP. 4 Treatment Sequencing With Androgen Receptor-Targeted Therapies for mCRPC

2 KOLs are featured in this series.

EP. 5 Overview of Abiraterone and the Differences Between Formulations

2 KOLs are featured in this series.

EP. 6 Combining Abiraterone with Steroids

2 KOLs are featured in this series.

EP. 7 The Importance of Serum Testosterone Levels With the Use of Androgen Receptor-Targeting Therapies

2 KOLs are featured in this series.

EP. 8 Clinical Attributes of Patients Who Would Benefit From Micronized Abiraterone

2 KOLs are featured in this series.

EP. 9 Dosing and Administration Considerations for Abiraterone Formulations

2 KOLs are featured in this series.

EP. 10 Access Challenges Regarding the Use of Abiraterone in Patients With mCRPC

2 KOLs are featured in this series.

EP. 11 Future Directions in mCRPC

To what extent do average serum testosterone levels guide selection between abiraterone formulations?
STAAR study: Average serum testosterone levels≤0.1 ng/dL occurred in 25% of patients treated with micronized formulation vs 17% of patients receiving the originator formulation.

Newsletter

Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.

Latest CME

DSUI Urology on the Beach

In-Person Event

DSUI Urology on the Beach

January 16-18, 2026

Community Oncology Connections™: Beyond the Basics—Revolutionizing Advanced Prostate Cancer Management With PSMA-Targeted Therapies | Texas

Community Oncology Connections™: Beyond the Basics—Revolutionizing Advanced Prostate Cancer Management With PSMA-Targeted Therapies | Texas

Jeremie Calais, MD, PhD; Qian Qin, MD

Case-by-Case: Application of HIF-PHIs for the Treatment of Anemia in Patients With CKD

Case-by-Case: Application of HIF-PHIs for the Treatment of Anemia in Patients With CKD

Glenn M. Chertow, MD, MPH; Anil K. Agarwal, MD, FACP, FASN, FNKF, FASDIN; Preethi Yerram, MD

Medical Crossfire® in Adjunctive Testing: Charting a New Course in Prostate Cancer Risk Assessment

Medical Crossfire® in Adjunctive Testing: Charting a New Course in Prostate Cancer Risk Assessment

Jason Hafron, MD; Aaron D. Berger, MD; Arpeet Shah, MD

Radioligand Therapy 101: The Science Behind the Strategy

Radioligand Therapy 101: The Science Behind the Strategy

Jeremie Calais, MD, PhD; Tanya B. Dorff, MD; Scott T. Tagawa, MD, MS, FACP, FASCO

Ready for Radioligand Therapy? Patient Selection and Sequencing Simplified

Ready for Radioligand Therapy? Patient Selection and Sequencing Simplified

Jeremie Calais, MD, PhD; Tanya B. Dorff, MD; Scott T. Tagawa, MD, MS, FACP, FASCO

BURST CME™ Resource Center: Integrating Novel PSMA-Directed Radioligand Approaches for Diagnosis and Management of Prostate Cancer

BURST CME™ Resource Center: Integrating Novel PSMA-Directed Radioligand Approaches for Diagnosis and Management of Prostate Cancer

Jeremie Calais, MD, PhD; Tanya B. Dorff, MD; Nerina McDonald, MSPAS, PA-C; Scott T. Tagawa, MD, MS, FACP, FASCO

Working Together: Overcoming Barriers to Optimize Outcomes in Patients Treated With Radioligand Therapy Through Multidisciplinary Care

Working Together: Overcoming Barriers to Optimize Outcomes in Patients Treated With Radioligand Therapy Through Multidisciplinary Care

Jeremie Calais, MD, PhD; Tanya B. Dorff, MD; Nerina McDonald, MSPAS, PA-C; Scott T. Tagawa, MD, MS, FACP, FASCO

Community Practice Connections™: Beyond the Basics— Revolutionizing Advanced Prostate Cancer Management With PSMA-Targeted Therapies

Community Practice Connections™: Beyond the Basics— Revolutionizing Advanced Prostate Cancer Management With PSMA-Targeted Therapies

Jeremie Calais, MD, PhD; Scott T. Tagawa, MD, MS, FACP, FASCO

Enhancing Prostate Cancer Outcomes – The Role of PSMA and Targeted Treatment Strategies

Enhancing Prostate Cancer Outcomes – The Role of PSMA and Targeted Treatment Strategies

Ana Kiess, MD, PhD; Erin Grady, MD, CCD, FACNM, FSNMMI; Himanshu Nagar, MD, MS; Scott T. Tagawa, MD, MS, FASCO, FACP

Burst CME™: Staying Informed and Up-To-Date on the Treatment of Lupus Nephritis

Burst CME™: Staying Informed and Up-To-Date on the Treatment of Lupus Nephritis

Michelle Petri, MD, MPH; Shivani Garg, MD, PhD

Burst CME™: Recognizing Lupus Nephritis—From Timely Diagnosis to Appreciating the Underlying Mechanisms of Disease

Burst CME™: Recognizing Lupus Nephritis—From Timely Diagnosis to Appreciating the Underlying Mechanisms of Disease

Michelle Petri, MD, MPH; Shivani Garg, MD, PhD

Guiding Prostate Cancer Diagnosis with Biomarker Testing

Guiding Prostate Cancer Diagnosis with Biomarker Testing

Aaron D. Berger, MD

Developing a Long-Term Monitoring Plan to Assess Prostate Cancer Risk

Developing a Long-Term Monitoring Plan to Assess Prostate Cancer Risk

Jason M. Hafron, MD

Burst CME™: Incorporating Multiparametric MRI to Guide Prostate Cancer Diagnosis

Burst CME™: Incorporating Multiparametric MRI to Guide Prostate Cancer Diagnosis

Stacy Loeb, MD, MSc, PhD (Hon)

Trending on Urology Times

GPS-ProtecT study launched to validate Genomic Prostate Score in active surveillance

Taylor Goodstein, MD, highlights contemporary experience with gene therapies for NMIBC

Real-World Evidence in mCSPC Management

Jim Hu, MD, discusses new posterior approach to nerve-sparing prostatectomy

Permanent J code for mitomycin for intravesical solution now in effect